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Transient receptor potential ankyrin 1 
that is induced in dorsal root ganglion neurons 
contributes to acute cold hypersensitivity 
after oxaliplatin administration
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Abstract 
Background: Peripheral cold neuropathic pain is a serious side effect of oxaliplatin treatment. However, the mecha-
nism of oxaliplatin-induced cold hyperalgesia is unknown. In the present study, we investigated the effects of oxalipl-
atin on transient receptor potential ankyrin 1 (TRPA1) in dorsal root ganglion (DRG) neurons of rats.
Results: Behavioral assessment using the acetone spray test showed that 3 and 6 mg/kg oxaliplatin (i.p.) induced 
acute cold hypersensitivity after 1, 2, 4, and 7 days. Real-time PCR showed that oxaliplatin (6 mg/kg) significantly 
increased TRPA1 mRNA expression in DRGs at days 1, 2, and 4. Western blotting revealed that oxaliplatin significantly 
increased TRPA1 protein expression in DRGs at days 2, 4, and 7. Moreover, in situ hybridization histochemistry revealed 
that most TRPA1 mRNA-labeled neurons in the DRGs were small in size. Oxaliplatin significantly increased co-local-
ization of TRPA1 expression and isolectin B4 binding in DRG neurons. Oxaliplatin induced a significant increase in 
the percent of TRPA1 mRNA-positive small neurons in DRGs at days 1, 2, and 4. In addition, we found that intrathecal 
administration of TRPA1 antisense, but not TRPA1 mismatched oligodeoxynucleotides, knocked down TRPA1 expres-
sion and decreased oxaliplatin-induced cold hyperalgesia. Double labeling showed that p-p38 mitogen-activated 
protein kinase (MAPK) was co-expressed in TRPA1 mRNA-labeled neurons at day 2 after oxaliplatin administration. 
Intrathecal administration of the p38 MAPK inhibitor, SB203580, significantly decreased oxaliplatin-induced acute cold 
hypersensitivity.
Conclusions: Together, these results demonstrate that TRPA1 expression via activation of p38 MAPK in DRG neurons, 
at least in part, contributes to the development of oxaliplatin-induced acute cold hyperalgesia.
Keywords: Oxaliplatin, Transient receptor potential ankyrin 1, p38 mitogen-activated protein kinase, Acute cold 
hyperalgesia, Peripheral neuropathic pain
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Background
Oxaliplatin is a platinum-based chemotherapeutic agent 
that is effective against advanced colorectal cancer. 
However, this drug induces painful peripheral neuropa-
thy as a dose-limiting side effect. Oxaliplatin-induced 
neurotoxicity manifests as rapid-onset neuropathic symp-
toms that are exacerbated by cold exposure and as chronic 
neuropathy that develops after several treatment cycles [1, 
2]. In rodents, a single injection of oxaliplatin induces cold 
and mechanical allodynia [3–5]. Oxaliplatin is metabolized 
to oxalate and dichloro (1,2-diaminocyclohexane)platinum 
[Pt(dach)Cl2] [6]; oxalate is related to cold hyperalgesia, 
and Pt(dach)Cl2 induces the mechanical allodynia [2].
Temperature is sensed by a subpopulation of periph-
eral primary afferent fibers known as thermoreceptors. 
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Several candidate thermo-sensor molecules have been 
identified that belong to the transient receptor potential 
(TRP) ion channel family [7]. Two of these ion channels, 
termed TRP ankyrin 1 (TRPA1) and TRP melastatin 8 
(TRPM8), have been proposed to function as cold trans-
ducers [8–10] and have been identified as cold-sensitive 
ion channels. TRPM8 is activated by menthol and cool-
ing, with an activation temperature of approximately 
25–28 °C [11, 12]. TRPA1, which is expressed by sensory 
neurons, is activated at approximately 17 °C, a tempera-
ture that is reported as painfully cold by humans [13–15]. 
Recently, Nassini et  al. reported that a single dose of 
oxaliplatin produces mechanical and cold hyperalgesia in 
rats, and this effect is selectively attenuated by a TRPA1 
antagonist [16]. In addition, mechanical and cold hyper-
algesia are absent in TRPA1-deficient mice [17]. Thus, 
TRPA1 may contribute to acute cold hypersensitivity 
evoked by administration of oxaliplatin.
Activation of p38 mitogen-activated protein kinase 
(MAPK) contributes to the development and maintenance 
of inflammatory and neuropathic pain [18–20]. p38 MAPK 
signaling can be activated in the DRG by administration of 
capsaicin or noxious thermal stimuli [21]. Activated p38 
MAPK in the DRG is thought to play an important role in 
oxaliplatin-induced acute cold hypersensitivity. However, 
the mechanisms of oxaliplatin-induced acute cold hyper-
sensitivity and activation of the p38 MAPK pathway have 
not yet been evaluated, and the mechanisms underlying 
the up-regulation of oxaliplatin-induced TRPA1 are still 
poorly understood. Thus, because TRPA1 is a sensor of 
cold temperatures, we hypothesized that up-regulation of 
TRPA1 via a p38 MAPK pathway mediates cold hyperal-
gesia induced by oxaliplatin. The aim of this study was to 
investigate the involvement of TRPA1 and p38 MAPK in 
DRGs in oxaliplatin-induced acute cold hypersensitivity.
Results
Effects of oxaliplatin on acute cold hypersensitivity
We first investigated the effect of oxaliplatin (1, 3, and 
6  mg/kg, i.p.) on acute cold hypersensitivity. Before the 
first single dose of oxaliplatin, we found no significant 
differences in the number of withdrawal responses in 
any groups in the acetone spray test. Oxaliplatin (1 mg/
kg, i.p.) did not affect the paw withdrawal response rate 
in the acetone spray test. However, the response rate was 
significantly increased with 3 and 6 mg/kg oxaliplatin in 
the acetone spray test at days 1–7 after a single dose of 
oxaliplatin compared to 5 % glucose treatment (Fig. 1).
Effect of oxaliplatin on expression of TRPA1 mRNA in DRG 
neurons
We investigated the expression of TRPA1 mRNA dur-
ing acute cold hypersensitivity after oxaliplatin admin-
istration. We removed DRGs (L4–6) at days 1, 2, 4, and 
Fig. 1 Time course of acute cold hypersensitivity after oxaliplatin administration. The acetone spray test was used to measure cold response (1, 
3, and 6 mg/kg, i.p.) in rats at days 1–7 after oxaliplatin administration. Data are the mean ± SEM of n = 8–10 rats. *P < 0.05, **P < 0.01, two-way 
ANOVA with Dunnett’s post hoc analysis compared to control (5 % glucose)
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7 after the start of 6  mg/kg oxaliplatin, and TRPA1 
mRNA expression was quantified with RT-PCR. As 
shown in Fig.  2a, 6  mg/kg oxaliplatin significantly 
increased TRPA1 mRNA expression in DRGs at days 
1 (127.9 ±  10.4 %, n =  4, P < 0.01), 2 (125.1 ±  10.8 %, 
n = 4, P < 0.01), and 4 (114.9 ± 7.3 %, n = 4, P < 0.05) 
compared to day 0 (100.0  ±  6.3  %). TRPA1 mRNA 
expression was maximally increased at day 1 and 
returned to control levels 7 days after administration of 
oxaliplatin (Fig. 2a).
Effect of oxaliplatin on TRPA1 protein expression
We removed DRGs (L4–6) at days 1, 2, 4, and 7 after the 
start of 6  mg/kg oxaliplatin administration, and TRPA1 
protein expression was quantified with western blot-
ting. As shown in Fig.  2b, 6  mg/kg oxaliplatin signifi-
cantly increased TRPA1 protein expression in DRGs at 
days 2 and 4. Protein expression at day 7 had begun to 
decrease, but remained significantly higher than at day 0. 
Up-regulation of TRPA1 protein was significant at day 2 
(116.1 ± 10.7 %, n = 4, P < 0.01) and maximal at day 4 
(123.9 ± 13.3 %, n = 4, P < 0.01; Fig. 2b) compared to day 
0 (100.0 ± 5.8 %).
Oxaliplatin increases TRPA1 mRNA‑labeled neurons as seen 
with in situ hybridization histochemistry (ISHH)
ISHH revealed that most TRPA1 mRNA-labeled neu-
rons in the DRGs (L4–6) were small or medium in size 
(Fig. 3a), consistent with previous studies [9–11]. Most 
TRPA1 mRNA-positive DRG neurons in oxaliplatin-
treated rats were small-sized neurons compared to 5 % 
glucose treatment (Fig. 3b). Thus, oxaliplatin increased 
the number of small-diameter DRG neurons that 
express TRPA1 mRNA. Using computerized image 
analysis, we found that oxaliplatin (6  mg/kg) induced 
a significant increase in the percentage of TRPA1 
mRNA-positive DRG neurons at days 1 (45.5 ±  3.9  %, 
n = 4, P < 0.01), 2 (53.0 ± 8.7 %, n = 4, P < 0.05), and 
4 (40.4 ± 7.0 %, n = 4, P < 0.05). The percent of TRPA1 
mRNA-positive neurons gradually declined, return-
ing to control levels by day 7 (Fig. 3c). These changes in 
TRPA1 were also confirmed with RT-PCR (Fig. 2). The 
results indicated that oxaliplatin increased the percent 
of TRPA1 mRNA-positive neurons as a result of up-
regulation of TRPA1 expression in small-diameter DRG 
neurons in particular.
TRPA1 gene knockdown prevents oxaliplatin‑induced 
acute cold hypersensitivity
Our results suggest that acute cold hypersensitivity after 
oxaliplatin administration is critically dependent on 
functional TRPA1 in DRG neurons. We therefore pre-
dicted that selective knockdown of TRPA1 expression 
would prevent oxaliplatin-induced acute cold hypersen-
sitivity. To test this, rats were intrathecally treated with 
either antisense oligodeoxynucleotides (AS-ODN) tar-
geting TRPA1 or control mismatched oligodeoxynucleo-
tides (MM-ODN) for 3 days before oxaliplatin (6 mg/kg) 
administration. The paw withdrawal response rate in the 
TRPA1 AS-ODN and MM-ODN groups was not differ-
ent in the water spray test (22 °C) (Fig. 4a). The increase 
in oxaliplatin-induced cold hypersensitivity in the paw 
withdrawal response rate in the acetone spray test was 
significantly less in the TRPA1 AS-ODN group at days 1, 
Fig. 2 Oxaliplatin administration increases TRPA1 mRNA and protein 
in DRGs. a Effect of oxaliplatin (6 mg/kg, i.p.) on TRPA1 mRNA expres-
sion in rat DRGs (L4–6) at days 0 (before administration), 1, 2, 4, and 7 
was measured. TRPA1 expression was normalized to β-actin expres-
sion. Histograms show the relative amount of TRPA1 mRNA in oxali-
platin-treated rats compared with day 0. Data are the mean ± SEM. 
n = 4 for oxaliplatin administration. *P < 0.05, **P < 0.01 versus day 
0. b Effect of oxaliplatin (6 mg/kg, i.p.) on TRPA1 protein expression in 
rat DRGs (L4–6). TRPA1 and β-actin protein in DRGs at days 0 (before 
administration), 1, 2, 4, and 7 was measured. TRPA1 expression was 
normalized to β-actin expression. Histograms show the relative 
amount of TRPA1 protein in oxaliplatin-treated rats. The western blot 
shows representative data. Data are the mean ± SEM. n = 4 each 
for 5 % glucose and oxaliplatin administration. *P < 0.05, **P < 0.01 
versus day 0
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2, and 4 than in the MM-ODN group (Fig. 4b). As shown 
in Fig. 4b, the TRPA1 AS-ODN group showed a signifi-
cant decrease in the paw withdrawal response rate at 
days 1 (54.3 ±  14.4 vs. 20.0 ±  11.4 %, n =  4, P < 0.05), 
2 (67.3 ± 5.4 vs. 14.3 ± 10.4 %, n = 4, P < 0.01), and 4 
(58.4  ±  7.4 vs. 20.9  ±  9.0  %, P  <  0.01, n  =  4). TRPA1 
MM-ODN did not affect oxaliplatin-induced acute 
cold hypersensitivity in rats. We also confirmed that 
the level of TRPA1 protein in the DRGs of the TRPA1 
Fig. 4 Effect of oxaliplatin on cold hypersensitivity after TRPA1 
knockdown in the acetone spray test and water spray test. Intrathe-
cal administration of TRPA1 AS-ODN prevents cold hypersensitiv-
ity induced by oxaliplatin (6 mg/kg, i.p.) as seen with the acetone 
spray test, but not the water spray test. The water spray test (22 °C) 
and acetone spray test at days 1, 2, 4, and 7 after oxaliplatin were 
measured in TRPA1 AS-ODN and TRPA1 MM-ODN treatment groups. a 
Histograms show the mean ± SEM of cold hypersensitivity at days 0 
(before administration), 1, 2, 4, and 7 after oxaliplatin administration in 
the water spray test (22 °C). b Histograms show cold hypersensitivity 
at days 0 (before administration), 1, 2, 4, and 7 after oxaliplatin admin-
istration in the acetone spray test. Data are the mean ± SEM. n = 4 
for oxaliplatin administration. *P < 0.05, **P < 0.01 versus TRPA1 MM-
ODN treatment groups. c The TRPA1 AS-ODN was effective at reduc-
ing TRPA1 protein expression. TRPA1 and β-actin protein in DRGs at 
day 2 after oxaliplatin administration (6 mg/kg, i.p.) was measured. 
TRPA1 expression was normalized to β-actin expression. Histograms 
show the relative amount of TRPA1 protein in oxaliplatin (6 mg/kg, 
i.p.)-treated rats. The western blot shows representative data. Data are 
the mean ± SEM. n = 4 for oxaliplatin administration. *P < 0.05 versus 
TRPA1 MM-ODN treatment groups
Fig. 3 Oxaliplatin increases TRPA1 mRNA as seen with in situ hybridi-
zation histochemistry in the DRG. Effect of oxaliplatin (6 mg/kg, i.p.) 
on TRPA1 mRNA expression in rat DRG (L4–6) neurons. a Photomi-
crographs showing in situ hybridization for TRPA1 mRNA at day 2 
after oxaliplatin (6 mg/kg, i.p.). TRPA1 mRNA-expressing small-sized 
neurons were more frequently observed after oxaliplatin treatment. b 
Size distribution of TRPA1-expressing neurons in DRGs in 5 % glucose- 
and oxaliplatin-treated rats. TRPA1 expression was distributed in all 
sizes of neurons, but most TRPA1 expression was found in small DRG 
neurons. c Histogram shows the percent of TRPA1-positive neurons 
relative to the total neurons. TRPA1 mRNA-expressing neurons were 
more frequently observed at days 1, 2, 4, and 7 after oxaliplatin 
administration (6 mg/kg, i.p.) compared to 5 % glucose-treated 
animals. Data are the mean ± SEM. n = 4 each for 5 % glucose and 
oxaliplatin administration. *P < 0.05, **P < 0.01 versus 5 % glucose
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AS-ODN-treated rats was significantly lower than in the 
MM-ODN-treated rats (Fig. 4c).
The effect of oxaliplatin on TRPA1 co‑localization 
with isolectin B4 binding in DRG neurons
We detected TRPA1 protein expression in DRG (L4–6) 
neurons at day 2 after oxaliplatin administration using 
immunohistochemistry. An increase in the frequency 
of TRPA1-positive cells was found in the oxaliplatin-
treated rats compared with 5  % glucose-treated rats 
(Fig.  5a, b). Using computerized optical density image 
analysis, we measured the optical density of individ-
ual DRG neurons that were TRPA1 positive. Next, we 
compared isolectin B4-binding small neurons (green in 
Fig.  5a) between oxaliplatin- and 5  % glucose-treated 
rats. TRPA1 expression (red in Fig. 5a) overlapped with 
isolectin B4 binding to neurons. Immunofluorescence 
double-labeling experiments revealed a pronounced 
overlap between small-diameter DRG neurons express-
ing TRPA1 and isolectin B4 binding (yellow in Fig. 5a, 
merged). In 5 % glucose-treated rats, approximately half 
of the isolectin B4-binding DRG neurons were immu-
nostained for TRPA1. The percent of TRPA1/isolectin 
B4 dual-positive cells relative to the total isolectin 
B4-binding neurons was significantly increased at 
day 2 after oxaliplatin administration (45.8  ±  5.0 vs. 
64.7 ±  3.9  %, P  <  0.05, n =  4) (Fig.  5b). Thus, oxalipl-
atin significantly increased expression of TRPA1 and 
isolectin B4 binding in DRG neurons.
Oxaliplatin increases co‑expression of TRPA1 mRNA 
and p‑p38 in neurons
We detected TRPA1 mRNA-labeled neurons in DRG 
(L4–6) neurons at day 2 after oxaliplatin administra-
tion using ISHH. We compared the expression of p-p38 
(red in Fig.  6a) between oxaliplatin- and 5  % glucose-
treated rats. TRPA1 mRNA-labeled neurons (green in 
Fig.  6a) overlapped with p-p38-positive neurons. Dou-
ble-labeling experiments revealed a pronounced overlap 
between DRG neurons expressing TRPA1 mRNA and 
those expressing p-p38 (yellow in Fig.  6a, merged). The 
percent of TRPA1 mRNA/p-p38 dual-positive neurons 
relative to the total p-p38-positive neurons was signifi-
cantly increased at day 2 after oxaliplatin administration 
(36.7 ±  5.0 vs. 59.6 ±  3.9  %, P  <  0.01, n =  4) (Fig.  6b). 
Oxaliplatin significantly increased expression of TRPA1 
mRNA and p-p38 in DRG neurons. TRPA1 mRNA/p-
p38 dual-positive neurons in oxaliplatin-treated rats were 
mainly small-sized neurons compared to 5  % glucose 
treatment (Fig. 6c). Thus, oxaliplatin increased the num-
ber of small-diameter DRG neurons that co-expressed 
TRPA1 mRNA and p-p38.
The effect of a p38 MAPK inhibitor (SB203580) 
on oxaliplatin‑induced acute cold hypersensitivity
To examine the functional consequences of p38 MAPK 
activation, we investigated whether inhibition of p38 
MAPK activation modifies the paw withdrawal response 
to oxaliplatin administration. To test this, rats were 
Fig. 5 Oxaliplatin increases TRPA1 protein expression as seen with immunohistochemistry in the DRG. a Effect of oxaliplatin (6 mg/kg, i.p.) on 
co-localization of TRPA1 protein expression with isolectin B4 binding in rat DRG (L4–6) neurons. The photomicrographs show representative data. 
Co-localization of TRPA1 expression (red) and isolectin B4 binding (green) is shown. Double-labeled neurons (arrowheads) are stained yellow in 
the merged panel. b Histogram shows the percent of TRPA1-positive neurons relative to isolectin B4-binding neurons. TRPA1 and isolectin B4 
co-localization was significantly higher on day 2 after oxaliplatin administration (6 mg/kg, i.p.) compared to 5 % glucose treatment. Data are the 
mean ± SEM. n = 4 each for 5 % glucose and oxaliplatin administration (6 mg/kg, i.p.). *P < 0.05 versus 5 % glucose
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Fig. 6 Effect of oxaliplatin on TRPA1 mRNA as seen with in situ hybridization histochemistry in rat DRG (L4–6) neurons. a Oxaliplatin (6 mg/kg, i.p.) 
increases the co-localization between TRPA1 and p-p38 MAP kinase in rat DRG (L4–6) neurons. The photomicrographs show representative data. 
Co-localization of TRPA1 mRNA (green) and p-p38 MAPK (red) is shown. Double-labeled neurons (arrowheads) appear yellow in the merged panel. 
b Histogram shows the percent of TRPA1 mRNA-positive neurons relative to p-p38-positive neurons. TRPA1 mRNA and p-p38 co-localization was 
significantly higher on day 2 after oxaliplatin administration (6 mg/kg, i.p.) compared to 5 % glucose treatment. Data are the mean ± SEM. n = 4 
each for 5 % glucose and oxaliplatin administration. *P < 0.05 versus 5 % glucose. c Size distribution of TRPA1 mRNA- and p-p38 MAPK-co-express-
ing neurons in DRGs in 5 % glucose- and oxaliplatin-treated rats. TRPA1 mRNA and p-p38 MAPK-co-expressing neurons were distributed among 
all sizes of neurons, but most co-expression was found in small DRG neurons. Data are the mean ± SEM. n = 4 each for 5 % glucose treatment and 
oxaliplatin treatment (6 mg/kg, i.p.). d Intrathecal administration of the p38 MAPK inhibitor, SB203580 (0.5 μg μL−1 h−1), significantly prevents the 
acute cold hypersensitivity induced by oxaliplatin (6 mg/kg, i.p.). The acetone spray test at day 2 after oxaliplatin was measured in SB203580 and 
20 % DMSO treatment groups. Data are the mean ± SEM. n = 4 each for 20 % DMSO treatment and oxaliplatin treatment (6 mg/kg, i.p.). **P < 0.01 
versus DMSO. ##P < 0.01 versus oxaliplatin
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intrathecally treated with the MAPK inhibitor, SB203580 
(0.5 μg μL−1 h−1), for 3 days before oxaliplatin (6 mg/kg) 
administration. The increase in oxaliplatin-induced acute 
cold hypersensitivity in the paw withdrawal response 
rate in the acetone spray test was significantly less in the 
SB203580 group at day 2 (Fig. 6d). As shown in Fig. 6d, 
6 mg/kg oxaliplatin significantly increased the paw with-
drawal response rate at day 2 compared to the DMSO 
control. We first showed that the p38 MAPK inhibi-
tor (SB203580) reversed oxaliplatin-induced acute cold 
hypersensitivity.
Discussion
Our data demonstrated that a single dose of oxaliplatin 
induced acute cold hypersensitivity in rats in a time- and 
dose-dependent manner. In previous behavioral studies, 
single or multiple doses of oxaliplatin produce cold allo-
dynia/hyperalgesia [2, 4, 16]. The results of the present 
study agree with these previously published findings. In 
patients, cold allodynia induced by oxaliplatin is transient 
and usually improves within 3–4 days [22]. However, in 
animals, the response to the acetone spray test or cold 
plate test is significantly increased with 6 mg/kg oxalipl-
atin from day 1 through day 7 after a single dose of oxali-
platin [4, 17, 23, 24]. Thus, one limitation of our study is 
this difference between the animal model and patients. 
However, the discrepancy between humans and rodents 
may be explained by differences in the dose, period of 
administration, and testing methods.
In the present study, we showed that a single dose of 
oxaliplatin increased TRPA1 mRNA and protein in rat 
DRGs. TRPA1 mRNA was observed 1 and 2  days after 
injection and then gradually decreased, whereas TRPA1 
protein increased 2  days after injection. Expression 
peaked on day 4 and was maintained until day 7 after 
injection. A recent study reported a transient increase 
in TRPA1 mRNA only 6  h after exposure of cultured 
rat DRG neurons to oxaliplatin [25]. Moreover, TRPA1 
mRNA is moderately and significantly increased in 
mouse DRGs after a single dose of oxaliplatin (3  mg/
kg), but no further increase is observed after 6  h [16]. 
TRPA1 mRNA levels, but not TRPM8 mRNA, are 
slightly increased in mouse DRGs 90  h after oxaliplatin 
(6 mg/kg) administration [26]. Moreover, TRPA1 mRNA 
expression levels are significantly increased in rat DRGs 
on day 3 after oxaliplatin (6 mg/kg) treatment [27]. Our 
data in this study revealed that TRPA1 mRNA remained 
elevated from day 1 to 4 after a single dose of oxaliplatin 
(6  mg/kg), whereas TRPA1 protein was observed from 
day 2 to 7. The time course of acute cold hypersensitiv-
ity (peak effect was observed at day 2) may be explained 
by the increase in TRPA1 mRNA and protein in DRGs. 
Thus, TRPA1 appears to be involved in acute cold hyper-
algesia induced by oxaliplatin. In addition, using ISHH, 
we found that oxaliplatin increased TRPA1 mRNA 
expression in rat DRG small neurons after days 1, 2, and 
4. TRPA1 mRNA-positive DRG neurons were mainly 
small-sized neurons. Taken together, our results support 
the suggestion that molecular biological data for TRPA1 
are related to the behavioral cold test. Thus, the sustained 
cold hypersensitivity induced by oxaliplatin, as observed 
by the ratio of neurons expressing TRPA1, increased after 
day 2. TRPA1 up-regulation likely plays an important role 
in nociceptive processing in oxaliplatin-induced periph-
eral acute cold hypersensitivity.
To determine whether small neurons expressed TRPA1 
protein, DRG sections were double-labeled for TRPA1 
and isolectin B4. The ratio of neurons expressing TRPA1 
among those that were isolectin B4 positive was signifi-
cantly higher in oxaliplatin-treated rats, confirming that a 
considerable number of C-fiber neurons began to express 
TRPA1 after oxaliplatin administration. TRPA1 expres-
sion is seen in many small myelinated axons (Aδ fibers, 
16.1 % of TRPA1 axons) as well as in unmyelinated axons 
(C fibers, 78  %) [27]. Thus, oxaliplatin increased the 
expression of TRPA1 in small DRG neurons, and TRPA1 
was responsible for oxaliplatin-induced acute cold hyper-
sensitivity. Kim and colleagues showed that almost half 
of the TRPA1-positive neurons in the trigeminal gan-
glion bind IB4 [27]. Moreover, Joseph et al. showed that 
intrathecal administration of the neurotoxin IB4-saporin, 
which selectively blocks IB4-positive nociceptors, com-
pletely prevented oxaliplatin-induced cold allodynia/
hyperalgesia [28]. Taken together, our data suggest that 
oxaliplatin may be involved in the increase in TRPA1 in 
DRG small neurons, resulting in acute cold hypersensitiv-
ity. Furthermore, cold hypersensitivity induced by a sin-
gle dose of oxaliplatin is inhibited in Trp1−/− mice [16]. 
Previous behavioral studies have shown that intrathecal 
administration of antisense TRPA1 inhibits inflamma-
tion and prevents nerve injury-induced cold hyperalgesia 
[19]. Consistent with these reports, we confirmed that 
oxaliplatin-induced acute cold hypersensitivity in rats on 
days 1, 2, and 4 was significantly inhibited by intrathecal 
administration of TRPA1 AS-ODN.
Several reports have demonstrated that the activation 
of p38 MAPK in DRG neurons is induced by not only 
peripheral inflammation but also axotomy, and corre-
sponding nociceptive behaviors are prevented when p38 
MAPK is inhibited [20, 29, 30]. Moreover, the effects of 
a p38 MAPK inhibitor on cold hyperalgesia are mediated 
by inhibition of p38 MAPK activation in the DRG [19]. 
The neurotoxicity of platinum derivatives is strictly linked 
to modifications induced by oxaliplatin on activation of 
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the MAPK pathway [31]. In addition, noxious cold stimu-
lation induces stimulus intensity-dependent p38 MAPK 
activation predominantly in TRPA1-expressing DRG 
neurons. For example, the activation of p38 MAPK path-
ways in DRG neurons by gastric distension-induced vis-
ceral pain may be correlated with the activation state of 
primary afferent neurons through TRPA1 [31]. In vitro, 
administration of oxaliplatin induces dose-dependent 
activation by phosphorylation of p38 MAPK in DRG 
neurons [32]. In the present study, we found that the 
expression of p-p38 MAPK was co-localized with TRPA1 
expression in small DRG neurons after oxaliplatin treat-
ment. Intrathecal administration of the p38 MAPK 
inhibitor, SB203580, prevented the oxaliplatin-induced 
acute cold hypersensitivity. Taken together, these find-
ings suggest that the activation of p38 MAPK pathways 
in the DRG by administration of oxaliplatin may be, at 
least in part, correlated with functional activity through 
TRPA1, and further, involved in the development of ther-
mal hyperalgesia.
Conclusion
The present data suggest that up-regulation of TRPA1 
in small neurons of DRGs probably plays a crucial role 
in the pathogenesis of acute cold hypersensitivity via 
activation of p38 MAPK after oxaliplatin administra-
tion. Our data also suggest that activation of p38 MAPK 
in the DRG may be a main mechanism of up-regulation 
of TRPA1 in small DRG neurons during the process of 
oxaliplatin-induced acute cold hypersensitivity.
Methods
Experimental animals
Male Wistar rats weighing 250–330  g (Japan Labora-
tory Animals, Inc., Tokyo, Japan) were used. All rats 
were housed individually under automatically controlled 
environmental conditions, using a 12-h light–dark cycle 
(lights on from 08:00 to 20:00) with free access to food 
and water. All animals were quarantined in centralized 
animal facilities for at least 7 days upon arrival. Each ani-
mal was used only once. Experiments were carried out 
according to the guidelines for animal care and use pub-
lished by the National Institutes of Health and the com-
mittee of Showa Pharmaceutical University.
Drug administration
One dose (1, 3, or 6  mg/kg) of oxaliplatin (ElplatR) was 
intraperitoneally (i.p.) administered (Yakult Co., Ltd., 
Tokyo, Japan). Oxaliplatin was dissolved in a 5 % glucose 
solution at a concentration of 2 mg/ml depending on the 
animal’s weight, to ensure intraperitoneal injections of 
less than 2.5  ml. The control groups were injected with 
5 % glucose solution. Volumes of the 5 % glucose solution 
were adjusted to the weight of each rat and injected by 
the same route in the control group.
Acetone spray test for acute cold hypersensitivity
Observers blinded to the experimental conditions tested 
the rats using the acetone/water spray tests at the same 
time on days 0–7 after oxaliplatin treatment. To estimate 
cold sensitivity of the paw, acetone (Kanto Chemical Co., 
Inc., Tokyo, Japan) or water (22 °C) was used, according 
to modification of previously described methods [33]. 
Rats were placed in a clear plastic box (23 × 23 × 12 cm) 
with a wire mesh floor and allowed to habituate for 
30  min prior to testing. After habituation, 50 μl fluid 
(acetone or water) was sprayed on the plantar surface of 
the hind-paws five times using a MicroSprayer® (Penn 
Century Inc., Philadelphia, PA, USA). Paw withdrawal, 
defined as flinching, licking, or biting of the limb, was 
measured for 1 min after the start of the acetone spray. 
For the water spray test, mineral water at 22  °C was 
used. The effects of acetone or water spray were repeat-
edly evaluated over time after oxaliplatin (1, 3, and 6 mg/
kg) or 5  % glucose administration. A group of animals 
given oxaliplatin or glucose was tested 1 day before drug 
administration and for 7 days after drug administration.
Quantitative real‑time polymerase chain reaction (RT‑PCR)
Rats were deeply anesthetized with pentobarbital (50 mg/
kg, i.p.) on days 1, 2, 4, or 7 after oxaliplatin administration 
(6 mg/kg, i.p.), and DRGs (L4–6) were removed. RNA was 
purified using TRIzol (Invitrogen, Carlsbad, CA, USA). 
Total RNA (1 μg) was used for cDNA synthesis with a 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). 
Quantitative RT-PCR was performed using an Applied 
Biosystems StepOne™ RealTime PCR System (Applied Bio-
systems, Tokyo, Japan), using EXPRESS SYBR® GreenER™ 
qPCR SuperMixes® and Two-Step qRT-PCR kits (Invit-
rogen), according to the manufacturer’s instructions. The 
cycling conditions for all primers were as follows: 2 min at 
50 °C to incubate uracil DNA glycosylase, 2 min at 95 °C, 
followed by 50 cycles consisting of two steps: 15 s at 95 °C 
(denaturation) and 1  min at 60  °C (annealing and exten-
sion). TRPA1 levels were evaluated by comparison with 
β-actin levels. Primer sequences were as follows: TRPA1, 
(forward) 5′-GGCATGTACAACGAAGTGATCAA-3′ and 
(reverse) 5′-CTGTGTTCCCATTCTCTCCTTCTAAA-3′ 
corresponding to the rat TRPA1 gene (GenBank: 
AY496961.1) and β-actin, (forward) 5′-CAGGTCATCAC 
TATCGGCAATG-3′ and (reverse) 5′-GAGACTACAACT 
TACCCAGGAAGGAA-3′ corresponding to the rat β-actin 
gene (Sigma-Aldrich, Inc., St. Louis, MO, USA). In all cases, 
the validity of amplification was confirmed by the presence 
of a single peak in the melting temperature analysis and lin-
ear amplification during the PCR cycles.
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Western blot analysis
On days 2, 4, and 7 after oxaliplatin (6 mg/kg, i.p.) admin-
istration, rats were deeply anesthetized with pentobar-
bital (50  mg/kg, i.p.). DRGs (L4–6) were collected and 
homogenized in cold extraction buffer consisting of 
10 mM Tris–HCl buffer at pH 7.5, 100 mM NaCl, 1 mM 
EDTA, 0.5 % Triton X-100, and 0.5 % deoxycholate. The 
homogenates were centrifuged for 30 min at 15,000×g at 
4 °C, and the supernatant was collected. Total protein of 
the supernatant (30 μg) was electrophoresed on an SDS–
polyacrylamide gel (7.5 %), and separated proteins were 
transferred onto polyvinylidene fluoride membranes. 
Anti-TRPA1 antibody (Alomone Labs, Jerusalem, Israel) 
diluted 1:200 was used, and anti-β-actin antibody (Sigma-
Aldrich) was used as an internal control. Horseradish 
peroxidase-labeled anti-rabbit antibody diluted 1:2000 
was used as the secondary antibody (Sigma-Aldrich). 
Specific bands were detected using enhanced chemilu-
minescence plus the TM Western Blotting Detection Kit 
(GE Healthcare, Buckinghamshire, UK) according to the 
manufacturer’s protocol. The intensities of immunoreac-
tive bands were analyzed with MultiGage Ver.3 software 
(Fuji Film, Tokyo, Japan).
Immunohistochemistry
Rats were deeply anesthetized with pentobarbital (50 mg/
kg, i.p.) on day 2 after oxaliplatin administration (6 mg/
kg, i.p.). Rats were perfused transcardially with 20  ml 
potassium-free phosphate-buffered saline (K+-free PBS; 
pH 7.4) followed by 50  ml 4  % paraformaldehyde solu-
tion. The DRGs (L4–6) were removed, post-fixed for 3 h, 
cryoprotected overnight in 25  % sucrose solution, and 
stored at −80 °C until use. DRGs were cut at 10 μm thick-
ness, thaw-mounted on silane-coated glass slides, and 
air-dried overnight at room temperature. DRG sections 
were incubated with excess blocking buffer containing 
2 % skim milk in 0.1 % Triton X-100 in K+-free PBS and 
subsequently reacted overnight at 4 °C with anti-TRPA1 
antibodies (Alomone Labs, 1:200) in 2  % bovine serum 
albumin/0.1  % Triton X-100 in K+-free PBS. The sec-
tions were then incubated in fluorescein isothiocyanate-
conjugated anti-rabbit IgG (Sigma-Aldrich, 1:100) for 1 h 
at room temperature. Double labeling studies for TRPA1 
and isolectin B4 from Bandeiraea simplicifolia were per-
formed using an immunofluorescent procedure. Sections 
were incubated with anti-TRPA1 antibody and FITC-
conjugated isolectin B4 (Enzo Life Science, Ontario, Can-
ada) in blocking buffer for 4 h at 4 °C. After washing with 
PBS, sections were incubated with Cy3-conjugated anti-
goat antibody (Bethyl Laboratories, Inc., Montgomery, 
TX, USA).
All sections were treated with Permafluor (Thermo 
Shandon, Pittsburgh, PA, USA) and cover-slipped 
and evaluated with an Olympus laser-scanning confo-
cal microscope (FLUOVIEW BW50, Olympus, Tokyo, 
Japan) at wavelengths of 488  nm and 568  nm. A total 
of five sections (90  μm apart) were randomly selected 
from each DRG. The proportion of TRPA1-positive cells 
was calculated according to the size of the cell body. At 
least 350 neurons from each DRG (L4–6) of each rat were 
measured.
In situ hybridization histochemistry (ISHH)
On day 2 after oxaliplatin (6 mg/kg, i.p.), rats were deeply 
anesthetized with pentobarbital (50  mg/kg, i.p.), per-
fused with 4  % paraformaldehyde, and lumbar DRGs 
(L4–6) were rapidly dissected. Following post-fixation 
and cryo-protection in 30 % sucrose in PBS, single DRGs 
were embedded in OCT, frozen at −80 °C, and sectioned 
at 10  μm thickness. Sections were thaw-mounted onto 
MAS-coated glass slides (Matsunami Glass Inc., Ltd., 
Osaka, Japan) and fixed in 4  % paraformaldehyde in 
PBS for 10 min. After washing in PBS, the sections were 
treated with 1  mg/ml proteinase K (Sigma-Aldrich) in 
PBS for 10  min at room temperature, post-fixed in the 
same fixative, acetylated with acetic anhydride in 0.1 M 
triethanolamine, prehybridized for 60 min at 55  °C, and 
hybridized with digoxygenin (DIG)-labeled RNA probes 
overnight at 55  °C. DIG-labeled sense and anti-sense 
RNA probes corresponded to nucleotides 302–788 of 
rat TRPA1 mRNA (AY496961). Following post-hybrid-
ization washes and blocking, sections were incubated 
for 120  min in anti-DIG antibody conjugated to alka-
line phosphatase (1:5000; Roche, Mannheim, Germany), 
and signal was visualized using nitro blue tetrazolium/
bromochloroindolyl phosphate substrates (Roche). An 
equivalent sense probe displayed no signal.
Fluorescence in situ hybridization (FISH) 
and immunofluorescence double staining
For double staining using FISH and immunofluorescence, 
the OCT-embedded DRG sections described above were 
first incubated with DIG-labeled sense and anti-sense 
RNA probes corresponding to nucleotides 302–788 of 
rat TRPA1 mRNA (AY496961), and then incubated with 
anti-phospho-p38 (p-p38) MAPK (Thr180/Tyr182)(3D7) 
rabbit mAb (1:50; Cell Signaling Technology, Danvers, 
MA, USA). Sections were incubated with anti-DIG-
FITC to detect TRPA1 mRNA and 2 µg/ml Alexa Fluor® 
594-labeled secondary antibody (Molecular Probes, Ina, 
Eugene, OR, USA) to detect phospho-p38 MAPK.
Image analysis
Signals were analyzed with fluorescence microscopy at 
400× magnification using a microscopy-digital cam-
era system. Experimenters who were unaware of the 
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experimental protocol counted cells in a blinded man-
ner. A total of five sections (90 μm apart) were randomly 
selected from each DRG. The ratio of TRPA1-positive 
cells in the total profile was calculated for days 0, 1, 2, 
4, and 7 after oxaliplatin or 5  % glucose treatment. Sig-
nal intensity and area frequency analysis of each neuron 
were calculated with ImageJ 1.46. Neurons were consid-
ered TRPA1 positive if their signal intensity was threefold 
higher than background. For the background, we meas-
ured the signal intensity in three areas outside the DRG 
and calculated the mean signal intensity. The propor-
tion of TRPA1-positive cells of the total was calculated 
according to the size of the cell body. At least 900 neu-
rons from each DRG (L4–6) of each rat were measured.
Intrathecal injection of AS‑ODN or the p38 MAPK inhibitor
Under sodium pentobarbital (50  mg/kg) anesthesia, 
the rat atlanto-occipital membrane was cut. A soft tube 
(Silascon, Kaneka Medix Company, Osaka, Japan; outer 
diameter, 0.64  mm) was inserted into the subarach-
noid space for a length of 8.0  cm to ensure that the tip 
reached the lumbar enlargement. The end part of the 
catheter was inserted caudally into the subarachnoid 
space through a small slit in the atlanto-occipital mem-
brane to extend 8.0 cm beyond the slit. The rostral part 
of the catheter was sutured to the occipital muscle to 
immobilize the catheter, and the wound was closed in 
two layers with 3-0 silk thread. To obtain sustained infu-
sion of AS-ODN targeting TRPA1 (0.5  nmol  μL−1  h−1) 
or MM-ODN (0.5 nmol μL−1 h−1), an ALZET® osmotic 
pump (7-day pump, 1 μL/h; DURECT) was filled with 
AS-ODN (5′-TCTATGCGGTTATGTTGG-3′) or MM-
ODN (5′-ACTACTACACTAGACTAC-3′) in saline. 
ODNs were intrathecally infused for 3 days, and then rats 
were given oxaliplatin or 5 % glucose. Rats that showed 
motor impairment were excluded from further analysis. 
Whether ODNs can reach DRGs in sufficient concentra-
tions by intrathecal delivery has been frequently ques-
tioned. However, several reports have demonstrated that 
intrathecally delivered ODNs accumulate in DRG cells 
[34, 35].
An ALZET osmotic pump (7-day pump, 1 μL/h; 
DURECT) filled with the p38 inhibitor, SB203580 
(0.5  μg  μL−1  h−1) (A.G. Scientific, Inc., San Diego, CA, 
USA), in 20 % dimethylsulfoxide (DMSO) was connected 
to the soft tube. SB203580 was intrathecally infused for 
3  days, and then rats were given oxaliplatin or 5  % glu-
cose. Rats that showed motor impairment were excluded 
from further analysis.
Statistical analysis
All data are expressed as the mean  ±  SEM. For the 
time course study of acute cold hypersensitivity after 
oxaliplatin administration, the significance of the dif-
ference among the groups was analyzed by two-way 
ANOVA, followed by Dunnett’s multiple comparison 
test. For other multiple group analyses, such as the effect 
of oxaliplatin on TRPA1 mRNA and protein expression, 
the significance of the difference among the groups was 
evaluated with one-way ANOVA, followed by Dunnett’s 
multiple comparison test. For analysis of two groups, 
such as vehicle versus oxaliplatin or MM-ODN versus 
AS-ODN, the significance of the difference between the 
groups was determined using the F-test, followed by Stu-
dent’s or Aspin-Welch’s t test. Statistical significance was 
established at P < 0.05.
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